EA
KRYS icon

Ellsworth Advisors’s Krystal Biotech KRYS Stock Holding History

Ellsworth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.08M Sell
3,261
-7
-0.2% -$2.42K 0.17% 106
2026
Q2 		$1.14M Buy
3,268
+23
+0.7% +$6.87K 0.19% 103
2026
Q1 		$838K Buy
+3,245
New +$863K 0.16% 117

Other funds holding KRYS

Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
TAM
Tealwood Asset Management Minneapolis, Minnesota $251M AUM 42.58% 1-Year Est. Return
TNAM
Terra Nova Asset Management New York $155M AUM 33.52% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Ellsworth Advisors's KRYS Position: Q3 2026 in Review

Ellsworth Advisors reduced its Krystal Biotech (KRYS) stake by 0.21% in Q3 2026, selling an estimated $2.42K and leaving 3,261 shares worth $1.08M. The position accounts for 0.17% of the portfolio, ranked #106.

Ellsworth Advisors first reported a position in KRYS in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.14M in Q2 2026. 26 funds tracked by Wall St. Rank hold KRYS as of Q3 2026.

  • Ellsworth Advisors held 3,261 shares of Krystal Biotech worth $1.08M as of Q3 2026.
  • Ellsworth Advisors sold 7 Krystal Biotech shares in Q3 2026, an estimated $2.42K.
  • Krystal Biotech made up 0.17% of Ellsworth Advisors's portfolio in Q3 2026, its #106 holding.
  • Ellsworth Advisors first reported a position in Krystal Biotech in Q1 2026 and has held it in 3 quarters since.
  • Ellsworth Advisors's Krystal Biotech position peaked at $1.14M in Q2 2026.
  • 26 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.